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ABSTRACT 
 
Background. Carbapenem-resistant Enterobacteriaceae, including Escherichia coli and 
Klebsiella pneumoniae, are newly emerging pathogens of public health importance. Currently no 
nationally representative or mandatory surveillance or reporting system exists to examine trends 
of these important pathogens.  
 
Objective. The purpose of the current study was to estimate trends in overall microbial burden 
and carbapenem resistance in E. coli and K. pneumoniae and to understand the extent to which 
hospitals which report to voluntary surveillance systems represent all hospitals in the United 
States. 
 
Design. We conducted a descriptive study to compare the hospitals participating in voluntary 
reporting systems of the University HealthSystem Consortium and the National Healthcare 
Safety Network with the Healthcare Utilization Project’s Nationwide Inpatient Sample, a 
nationally representative sample of hospital discharges.  
 
Methods. Descriptive analyses examined hospital characteristics (region, bed size, hospital 
control, teaching status, case mix index) and patient characteristics (age, sex, race/ethnicity, 
admission source, admission type, discharge status, primary payer) of participant hospitals versus 
all US hospitals. ICD-9-CM codes identified discharges coded for E. coli and K. pneumoniae 
diagnoses; linear regression was used to evaluate trends in overall microbial burden of E. coli 
and K. pneumoniae in all US Hospitals and US Academic Centers. Trends in E. coli and K. 
pneumoniae resistance to carbapenem were also evaluated in hospitals participating in voluntary 
surveillance systems (n=13).  
 
Results. Between 2002 and 2007, slight increasing trends in burden of both E. coli and K. 
pneumoniae were observed (E. coli: slope = 0.0537; K. pneumoniae slope = 0.0168). Hospitals 
participating in voluntary surveillance systems are larger and care for fewer elderly patients than 
all US hospitals.   
 
Conclusions. These results suggest that hospitals that participate in voluntary surveillance 
systems like the National Healthcare Safety Network and the University HealthSystem 
Consortium may underrepresent trends in smaller hospitals, as well as those that treat elderly 
patients. Increasing overall burden of infection due to these isolates only reinforces the 
importance carbapenem resistance in E. coli and K. pneumoniae. This important public health 
threat may warrant the creation of a national, mandatory reporting system for these and other 
antimicrobial resistant organisms.  
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INTRODUCTION 
 
 Antimicrobial resistance, especially in heath care settings, has emerged as a significant 
public health threat.1 As multidrug resistant organisms have increased, so has use of broad 
spectrum agents to treat them.1 With their broad spectrum activity for gram positives, gram 
negatives and anaerobic bacteria,2 carbapenems are frequently used as a last line of therapy.3,4   
 Newer antimicrobial resistant species such as Carbapenem-resistant Enterobacteriaceae 
(CRE), including Escherichia coli and Klebsiella pneumoniae are beginning to emerge. 
Enterobacteriaceae are gram-negative bacteria which are part of the normal human intestinal 
flora and are frequently spread via fecal-oral contamination.1 Pathogenic isolates can be carried 
in the gut for years in healthy adults and only emerge when intestinal conditions change.1  
 The first carbapenem resistance was seen in K. pneumoniae in 2000 in a hospital in New 
York city;5 the first carbapenem hydrolyzing enzymes in E. coli isolates were found in 2005.6 
Most alarming was the discovery of a community-associated isolate of carbapenem-resistant E. 
coli in Greece in 2009.7 CRE was originally identified in the Northeast United States,5 but are 
now beginning to spread in the United States and Europe.8   
 The emergence of CRE is a great public health concern because there is no reliable 
treatment. CRE are typically resistant not only to carbapenems, but also to polymixin B sulfate 
and third generation cephalosporins.5 In addition, many carbapenem resistant isolates of K. 
pneumoniae also possess extended spectrum beta-lactamases,5 and genes conferring resistance 
may be accompanied by virulence factors.1 In many cases, in vitro analysis has shown some 
isolates to be susceptible to tigecycline, gentamicin, and colistin.5,9-11 Clinical treatment 
successes have resulted from combinations of gentamicin and colistin12 or tigecycline and 
colistin.13 In a case control study, removal of infection site was also part of a successful 
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treatment strategy.14 With few novel treatment options in development, treatment of CRE 
infections remains challenging.  
 Despite the severity of the emerging CRE and other multi-drug resistant organisms, the 
US currently has only voluntary antimicrobial resistance surveillance systems. Due to their low 
incidence in any single institution, it is likely that current, voluntary public health surveillance 
systems underrepresent the spread of these organisms.1 One surveillance system currently in use 
is the National Healthcare Safety Network. Designed to be a national surveillance system for 
both patient and healthcare personnel safety, it began collecting data from participant hospitals in 
2005.15 Another example is the University HealthSystem Consortium which, represents 
approximately 90% of the United States’ non-profit academic medical centers,16 and through 
collaboration among participant hospitals, has provided a limited mechanism of surveillance of 
data from its member organizations since 2002. No single mandatory reporting system exists to 
track the emergence and increase of these dangerous pathogens. The purpose of this study was 
twofold.  First, we estimated trends in both overall microbial burden and carbapenem resistance 
in E. coli and K. pneumoniae. Second, we sought to understand the extent to which hospitals 
pzrticipating in voluntary surveillance systems represent all hospitals in the United States.   
 
 
METHODS  
 
 We conducted a descriptive study to evaluate the extent to which voluntary public health 
reporting surveillance systems of carbapenem-resistant Enterobacteriaceae (CRE) may 
adequately represent all hospitals in the US. This study was not funded and the authors have no 
conflicts of interest to disclose.  
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Data Sources  
 Between September 2009 and January 2010, we thoroughly investigated multi-site data 
sources of antimicrobial resistance and identified two:  the National Healthcare Safety Network 
(NHSN) and the University HealthSystem Consortium (UHC).  We also identified two data 
sources which provide nationally representative hospital estimates: the National Hospital 
Discharge Survey and the Healthcare Utilization Project Nationwide Inpatient Sample (HCUP-
NIS).  While the latter data sources both enable nationally representative estimates of hospital 
discharges, we selected the HCUP-NIS for three reasons. First, its larger sample size and greater 
number of available diagnosis codes enabled estimation of rare events (such as CRE) with 
greater precision. Second, this source provided a more extensive array of data elements 
important for this research. Third, the HCUP-NIS provided data specifically on hospital 
characteristics, which allowed stratification by teaching status. Each data source used in final 
analysis is discussed in detail below.  
The University HealthSystem Consortium (UHC) 
 The University HealthSystem Consortium (UHC) is composed of 107 participant 
academic medical centers and 233 of their associated hospitals, representing approximately 90% 
of the United States’ non-profit academic medical centers.16 The UHC provides a mechanism for 
collaboration for research across academic medical centers, which are geographically distributed 
throughout the US.16  Approximately 75 academic medical centers participating in the UHC 
Clinical Database/Resource Manager module were approached by investigators at VCU for 
participation in surveillance of microbial-resistance rates. Investigators requested antibiograms 
from each hospital for each year from 2002 to 2008. Hospitals were provided with a $100 
incentive per year for sharing their data. Isolates were categorized as either susceptible or 
resistant; each hospital used their own standards to measure antimicrobial sensitivity (not 
reported). Hospitals were considered “UHC Participant Hospitals” and included in descriptive 
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distribution analysis if they contributed antibiogram data for at least one year in the study period 
(2002-2008, n=42). Hospitals were included in descriptive trend analysis only if data were 
available for all years in the study period (2002-2008, n = 13). 
National Healthcare Safety Network (NHSN) 
 Data from the National Healthcare Safety Network (NHSN) are not available publicly. 
While we were unable to secure data from the NHSN, we were able to extract data from a 
published report based on the NHSN.15 The NHSN was implemented in 2005, integrating three 
former systems: the National Nosocomial Infections Surveillance (NNIS) system, the Dialysis 
Surveillance Network and the National Surveillance System for Healthcare Workers.  Managed 
by the Centers for Disease Control and Prevention Division of Healthcare Quality Promotion, the 
NHSN compiles monthly electronically reported surveillance data on healthcare associated 
infections in approximately 460 participant healthcare facilities.15  
Healthcare Cost and Utilization Project- Nationwide Inpatient Sample (HCUP-NIS) 
 The Nationwide Inpatient Sample (NIS) is part of the Healthcare Cost and Utilization 
Project (HCUP) sponsored by the Agency for Healthcare Research and Quality. HCUP-NIS data 
are collected to track and analyze national trends in health care utilization, access, charges, 
quality and outcomes.17  
 The HCUP-NIS uses about 1,000 hospitals to draw a nationally representative, complex 
sample of US non-federal, short-term, general, specialty and non-institutional community 
hospitals. From each sampled hospital, all discharges for the sample year are included, totaling 5 
to 9 million annual discharges, enabling analyses of rare conditions such as E. coli and K. 
pneumoniae. Available data contain both hospital and patients characteristics; the number of 
included diagnosis codes per discharge varies over time and by state.17,18 
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ANALYSIS 
Evaluation of the National Burden of Total Escherichia coli and Klebsiella pneumoniae 
Diagnoses 
 We evaluated trends in the national burden of Escherichia coli and Klebsiella 
pneumoniae infections from all US Hospitals and US Academic Centers. Hospital discharge data 
from the HCUP-NIS were used to measure the total national burden of E. coli and K. 
pneumoniae diagnoses (regardless of antibiotic susceptibility). As the number of ICD-9-CM 
codes captured in the HCUP-NIS varies over time and by state, up to 15 International 
Classification of Disease (ICD)-9-CM codes were captured for each discharge record. All 
infection diagnosis codes of either infection (E. coli: 008.0, 008.00, 008.01, 008.02, 008.03, 
008.04, 008.09, 038.42, 041.4, 482.82; K. pneumoniae: 482.0, 041.3) were aggregated separately 
by year. Thus for each year, the proportion of hospital discharges with a diagnosis of E. coli or 
K. pneumoniae was calculated for 2002-2007, the most recently available data. 
 From these aggregated data, we developed two linear regression models; one using the 
dependent variable for presence of any ICD-9-CM code for E. coli, and one for K. pneumoniae. 
Each model included a single determinant- year. We interpreted the beta coefficient for the 
determinant as the change in proportion of diagnoses of E. coli (or K. pneumoniae) per one unit 
increase in year.    
Carbapenem Resistance Trends among Select UHC Participant Hospitals 
 Using antibiogram data available from the UHC Participant Hospitals, we conducted a 
descriptive evaluation of CRE resistance trends. Aggregate incident annual sensitivity data on 
carbapenem resistant isolates of Klebsiella pneumoniae and Escherichia coli were extracted from 
available antibiograms for analysis. Carbapenem resistance was normalized per 1,000 discharges 
annually for each species. As there were only 13 hospitals contributing data for all years, no 
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statistical tests were completed; data were plotted to visually inspect for descriptive trends in 
resistance.  
Comparison of Patient and Hospital Characteristics 
   To assess the extent to which hospitals participating in non-mandatory surveillance of 
CRE are similar to all hospitals nationwide, and whether discharges from these participant 
hospitals are similar to those from hospitals nationwide, we first examined which conceptual 
domains were available for analysis across both HCUP-NIS and UHC data sources. Once 
identified, we compared aggregated discharge-level and hospital-level characteristics.  To better 
approximate the population of academic medical centers from which UHC hospitals are selected, 
stratified analysis using hospitals from the HCUP-NIS was completed using two samples: 1) All 
US Hospitals: All hospitals sampled by the HCUP-NIS and 2) US Academic Centers: HCUP-
NIS Academic Medical Centers, limited to self-identified teaching hospitals. 
 The comparisons of interest were 1) all US Hospitals versus UHC Participant Hospitals; 
and 2) US Academic Centers versus UHC Participant Hospitals.  For analysis of HCUP-NIS 
data, we weighted for complex survey design using appropriate SAS survey procedures. P-values 
based on large samples such as this one are rarely of use because unimportant differences will be 
statistically significant.19 Therefore, we a priori used an absolute difference of 5% in 
distributions to indicate evidence of meaningful differences. 
 Discharge-level characteristics included: patient age group (younger than 18; 18-30 
years; 31-50 years; 51-64 years; 65 and older), gender, race/ethnicity, (White; Black/African 
American; Hispanic/Latino; Asian/Pacific Islander; American Indian/Alaskan Native), admission 
source (emergency room; another hospital; another facility; court/law enforcement; routine, birth 
or other), admission type (emergency; urgent care; elective; newborn; trauma center), discharge 
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status (died or did not die during hospitalization), and primary payer source (Medicare; 
Medicaid; private insurance or HMO; self pay; no charge for provided service; other). 
 Hospital-level variables included: geographic region, teaching status, bed size, hospital 
control, and mean case mix index. Region was defined using four regions (Northeast, Midwest, 
South, West), as characterized by the US Census Bureau. Hospital teaching status was self-
designated by each facility as teaching or non-teaching. For HCUP-NIS data, bed size was 
categorized as “small” “medium” or “large”, and was based on the number of hospital beds 
specific to the individual hospital’s region, location and teaching status, as described 
previously.17 To approximate this distribution, UHC hospital bed sizes were divided similarly to 
teaching centers captured by the HCUP-NIS: small, (< 250 beds) medium (250-399 beds) and 
large (> 400 beds). NHSN bed size analysis was extracted from an available report15 and was 
categorized as small, (< 200 beds) medium, (200 - 499 beds) and large (> 500 beds).  
 For the HCUP-NIS, when the sample size of hospitals was sufficiently large, hospital 
control was stratified as “public”, “non-profit”, and “proprietary.” For smaller strata, 
stratification was simply “public” and “private, collapsed.” For all other strata, no stratification 
was done due to small sample size, all hospitals were categorized as “collapsed, no control 
stratification done,” as described previously.20 
 Hospital case mix index (CMI) was calculated using diagnosis related group (DRG) 
relative weights downloaded from the Centers for Medicare and Medicaid Services.21 DRG 
weights were applied to each discharge based on reported DRG and then hospital CMI was 
calculated as described previously.22 CMI for each hospital from the HCUP-NIS were averaged, 
resulting in a mean CMI across all US Hospitals and US Academic Centers (assessed 
separately). For UHC Participant Hospitals, CMI was provided for each hospital, and a mean 
CMI measure was calculated.  
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RESULTS 
Evaluation of the National Burden of Escherichia coli and Klebsiella pneumoniae  
 Figure 1 shows the proportion of hospital discharges with a diagnosis of E. coli (Panel A) 
and K. pneumoniae (Panel B) for all US Hospitals and US Academic Centers. Between 2002 and 
2007, increases in the proportion of discharges for both E. coli and K. pneumoniae were 
observed. In 2007, an estimated 149,767 hospital discharges included codes for E. coli and 
562,809 for K. pneumoniae (among all US Hospitals). In both cases, higher E. coli and K. 
pneumoniae diagnosis rates were seen at US Academic Centers than at all US Hospitals. For all 
discharges from US Hospitals with a diagnosis of E. coli or K. pneumoniae, evidence of slight 
positive linear trends were shown for both species (E. coli: slope = 0.0537, Std. Err. = 0.00547; 
K. pneumoniae slope = 0.0168, Std. Err. = 0.00197). For discharges from US Academic Centers, 
evidence of positive linear trends were also shown for both species (E. coli: slope =0.0489, Std. 
Err. = 0.00580; K. pneumoniae slope = 0.01993, Std. Err. = 0.00113).  
CRE Antibiogram Trends among UHC Participant Hospitals 
 Figure 2 shows the trends in aggregate carbapenem resistance of Klebsiella pneumoniae 
and Escherichia coli. For carbapenem resistance in E. coli, no clear directional trend was seen, 
other than a nominal decrease in resistance in 2005. Hospital-level resistance rates in this species 
seem to be stable for the years evaluated. For K. pneumoniae, the data point toward evidence of a 
slight decrease in resistance until 2005, at which point an increasing trend begins to emerge. 
Current rates are nominally higher than those found earlier in this decade (data not shown).  
Comparison of Patient Characteristics 
 Table 1 shows the comparison of discharges from hospitals which participate in voluntary 
surveillance systems of CRE to discharges from all US hospitals, as well as all US Academic 
Centers. Overall, characteristic distributions of discharges from UHC Participant Hospitals 
approximated all US Academic Hospitals. There were meaningful differences between hospitals 
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voluntarily reporting CRE surveillance data and all US hospitals with respect to patient age, 
race/ethnicity, admission source and primary payer source.  
 More discharges from all US hospitals were from patients 65 or older (US Hospitals: 
33.5%, US Academic Centers: 29.1% and UHC Participants: 24.3%) and had Medicare as their 
primary payer source (US Hospitals: 36.4%, US Academic Centers: 31.9%, and UHC 
Participants: 29.5%). With respect to reported race/ethnicity, discharges from all US Hospitals 
were more frequently White (US Hospitals: 67%, US Academic Centers: 59.6% and UHC 
Participants: 60.7%), while discharges from UHC Participant Hospitals were more frequently 
Black/African American (US Hospitals: 15%, US Academic Centers: 19.2%, UHC Participants: 
24.7%).  
 Differences were also observed for admission source: discharges from all US Hospitals 
were more likely admitted from the emergency room, (US Hospitals: 44.5%, US Academic 
Centers: 42.8%, and UHC Participants: 39.4%) while those from UHC Participant Hospitals 
were more likely admitted from another hospital (US Hospitals: 3.3%, US Academic Centers: 
4.6%, UHC Participants: 7.9%).  
Comparison of Hospital Characteristics  
 Table 2 shows the comparisons of hospital characteristics: hospitals who voluntarily 
report CRE surveillance rates to all US Hospitals and US Academic Centers. UHC Participant 
Hospitals were better approximated by US Academic Centers than by all US Hospitals. Relative 
to all US hospitals, the UHC Participant Hospitals overrepresented the Northeast, 
underrepresented the Midwest and Southwest. UHC Participant Hospitals underrepresented small 
hospitals overall, as well as small academic hospitals (US hospitals: 45.2%, US Academic 
Centers: 28.0%, UHC Participants: 4.8%). When comparing UHC Participant Hospitals to 
NHSN Participant Hospitals, UHC Hospitals were more likely to be large (UHC: 73.8%, NHSN: 
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20.5%). All UHC Participants Hospitals were non-profit teaching centers. While only 18.2% of 
all US Hospitals are teaching centers, because of UHC’s deliberate sampling on academic 
medical centers, 100% of their hospitals are teaching centers. UHC Participant Hospitals also 
had a higher mean case mix index (CMI = 1.64, Std. Dev. = 0.18) compared to all US Hospitals 
(CMI = 1.18, Std. Dev. = 0.0005) and US Academic Centers (CMI = 1.25, Std. Dev. = 0.0009).  
 
DISCUSSION 
  
 Overall, we observed slight increased trends in hospital discharges coded E. coli and K. 
pneumoniae diagnoses. No distinct trend in carbapenem resistance in E. coli was observed in the 
13 hospitals with consistent contributions to the voluntary reporting system, but suggestions of 
an increase in carbapenem resistance in K. pneumoniae since 2005 is apparent. We found that 
hospitals participating in volunteer CRE surveillance systems may not adequately represent all 
US hospitals.  Hospitals participating in voluntary reporting systems underrepresent hospitals in 
the South and Midwest US. Further, the hospitals voluntarily reporting are likely not capturing 
trends or resistance in small hospitals, as well as proprietary or public hospitals. While discharge 
patient characteristics of hospitals participating in voluntary reporting systems for CRE better 
approximate US Academic Centers than by all US Hospitals, the participating hospitals tend to 
underrepresent patients aged 65 and older and Medicare recipients. Conversely, UHC Participant 
Hospitals also over-represent people who were Black/African American. Discharges from UHC 
Participant Hospitals were more frequently admitted from other hospitals.   
 Larger hospitals more frequently participate in studies of organizational and procedural 
determinants of infection and control and patient safety programs,23-25 though results presented 
here indicate that smaller hospitals actually make up the plurality of all US Hospitals. Larger, 
teaching, urban hospitals may have a better quality of care than non-teaching, small, rural 
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hospitals.26 For-profit hospitals may have higher mortality rates than public or non-profit 
hospitals, and private teaching hospitals have lower mortality rates than private non-teaching 
hospitals.27  Larger hospitals and teaching hospitals have higher rates of several antimicrobial 
resistant organisms.28 Larger hospitals are also more likely to have staff infection control 
specialists and/or laboratory personnel23 who may more easily facilitate surveillance and 
reporting internally and externally. Teaching hospitals are also more likely to have an accurate, 
disseminated and up-to-date antibiogram,24 typically used empirically to aid in clinical decision 
making. For-profit hospitals tend to detect and internally report antimicrobial resistance less 
frequently than other hospitals.24 Importantly, evidence suggests that antimicrobial monitoring 
and control systems at individual institutions are more frequently implemented as a reaction to 
high resistance rates, rather than proactively for prevention.24 As such, interpreting findings from 
hospitals participating in voluntary surveillance systems may not adequately capture emerging 
trends in resistance. 
While increasing age is predictive of CRE infection, gender was not found to be 
predictive;3 these and other demographic factors, like race/ethnicity, warrant further 
investigation. Typically, independent predictors of CRE infection comprise use of antibiotics,3 
including carbapenems,3,10,29 and cephalosporins;4,29 aminoglycosides have previously been 
shown as protective.4 Conflicting evidence in the literature exists over the importance of 
fluoroquinolones as predictive3,4,10 or protective29. Poor functional status and illness severity 
have also been shown to be predictive,3,4 while presence of comorbid conditions was not 
associated.4 Stay in the intensive care unit (ICU) has also been predictive of resistant K. 
pneumoniae isolation in some studies,3,10 while conflicting evidence is indicated in another.29  
 While overall the proportions of discharges coded with diagnoses of E. coli or K. 
pneumoniae are small (~1%), our study indicated evidence of slight increasing trends in both E. 
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coli and K. pneumoniae, coupled with the rise in resistance in K. pneumoniae. If overall burden 
is increasing, so is to the opportunity for resistance. Without proper, mandatory reporting and 
surveillance measures for these important public health pathogens, it is impossible to monitor 
true nationwide prevalence in CRE bacteria. Although current mandatory monitoring of 
“traditional” communicable disease by state health departments and the Centers for Disease 
Control and Prevention is far from perfect, these systems provide mechanisms of surveillance 
and evaluation to drive program planning at all levels of government, and are especially effective 
when electronic reporting is used.30,31 For a program mandating reporting of health-care 
associated infections to come to fruition, it is imperative that this issue become both an 
ideological and fiscal priority.  
  Proper surveillance of national trends may spur diffusion of promising prevention and 
infection control efforts. In a New York hospital where CRE infections are becoming endemic in 
the ICU, a comprehensive intervention including cohorting of specific patient groups, routine 
rectal surveillance, increased contact isolation and hand hygiene vigilance, and decontamination 
of the environment was successful in mitigating an outbreak of CRE.11 Improvements in hand 
hygiene, contact precautions and antimicrobial use have also been suggested as prevention 
mechanisms for CRE infections.32 These and other mechanisms of prevention will no doubt save 
time, finances and lives if CRE and other antimicrobial resistant infections can be prevented.  
 This study must be considered with certain caveats. First, we were only able to evaluate 
antibiogram resistance in a very small sample and each hospital used independent testing 
methods (not reported). Resistance in CRE can be measured in one of several ways, including 
antibiotic sensitivity analysis,12,33 the Hodge test or modified versions,33 or PCR,33,34 
Nevertheless, all methods are imperfect at detecting CRE in vitro,5,33 especially typical and 
routine automated methods.5,35. Second, the extent to which we were able to explore hospital and 
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patient characteristics was a function of the data elements available. Yet, we were able to provide 
a comparison of relatively small reporting systems with a large, nationally representative sample 
of patient discharges and hospital characteristics which provides accurate estimates of US 
hospitals. The HCUP-NIS is well suited for examining rare diagnoses like E. coli and K. 
pneumoniae and allowed us to stratify hospitals by teaching status. Lastly, the number of ICD-9-
CM codes reported to HCUP varied through time and place.  Although we analyzed trend data 
according to HCUP standards, it may be that increasing trends were a function of increases in the 
number of diagnoses reported rather than true increases in burden. 
 
CONCLUSIONS 
 Antimicrobial resistance has emerged as a significant public health threat, with the past 
quarter-century “ushering in the era of multidrug resistance.”1 Carbapenem resistance is newly 
emerging in isolates like Escherichia coli and Klebsiella pneumoniae. Increasing overall burden 
of infection due to these isolates only reinforces CRE as an important public health threat and 
may warrant the creation of a national, mandatory reporting system for these and other 
antimicrobial resistant organisms. Due to the current climate of pharmaceutical production, 
preventing the further creation and spread of drug-resistant isolates will not likely stem from new 
therapeutics, but rather from control, isolation and antimicrobial stewardship practices across 
healthcare settings.32 
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Figure 1. The National Burden of Escherichia coli and Klebsiella pneumoniae 
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Figure 2. Carbapenem Resistance Trends in Escherichia coli and Klebsiella pneumoniae- select* 
UHC Participant Hospitals (n=13) 
 
 
*There were 13 UHC Participant Hospitals for which data were available for all years; Means reflect all 13 hospitals. Individual 
hospitals were not graphed here if data for all years reflected no resistance (0.000). 
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Table 1: Patient Level Variables, 2007 Discharges 
    
US  
Hospitals 
US 
Academic 
Centers 
UHC 
Participant 
Hospitals 
     Sample Size                8,043,415 3,758,898 1,268,496 
     Weighted Sample Size 39,541,948 18,760,902 N/A 
    
 
Weighted 
Percentage 
Weighted 
Percentage Percentage 
Patient Age       
  Younger than 18 years 17.2 19.2 16.2
  18 to 30 years 12.9 13.3 14.4
  31 to 50 years 19.7 21.0 24.0
  51 to 64 years 16.8 17.4 21.1
  65 and older 33.5 29.1 24.3
Patient Sex    
  Female 58.8 57.6 54.4
Patient Race/Ethnicity    
  White 67.0 59.6 60.7
  Black or African American 15.0 19.2 24.7
  Hispanic or Latino 14.2 16.4 11.5
  Asian or Pacific Islander 0.9 1.1 2.5
  Am. Indian/Alaskan Native 2.9 3.6 0.5
Admission Source    
  Emergency Room 44.5 42.8 39.4
  Another Hospital 3.3 4.6 7.9
  Another Facility 1.3 1.2 1.5
  Court/Law enforcement 0.1 0.1 0.1
  Routine, Birth or Other 50.7 51.2 50.4
Admission Type    
  Emergency 45.7 45.6 41.3
  Urgent Care 17.9 16.2 19.3
  Elective 25.0 26.2 28.1
  Newborn 11.2 11.6 9.2
  Trauma Center 0.2 0.4 1.3
Discharge Status    
  Died during hospitalization 1.9 1.9 2.2
Primary Payer Source    
  Medicare 36.4 31.9 29.5
  Medicaid 19.4 21.3 22.1
  Private Insurance 34.8 36.4 36.7
  Self Pay 5.3 5.6 5.4
  No Charge for Service 0.5 0.7 0.0
  Other  3.5 4.0 5.5
  
E. Smith 17  
 
 
Table 2: Hospital Level Variables, 2007 
  
US  
Hospitals 
US  
Academic 
Centers 
UHC 
Participant 
Hospitals 
NHSN 
Participant 
Hospitals 
Sample Size 1,044 191 42 462 
Wt. Sample Size 5,099 927 N/A N/A 
  
 
Weighted 
Percentage 
Weighted 
Percentage Percentage Percentage 
Region         
 Northeast 12.8 24.4 26.2
 Midwest 29.2 27.3 21.4
 South 39.9 31.0 31.0
 West 18.2 17.2 21.4
Bed Size *      
 Small 45.2 28.0 4.8 32.6
 Medium 24.3 28.7 21.4 46.9
  Large 30.6 43.3 73.8 20.5
Hospital Control * 
 Public 18.2 0.0 0.0
 Non-profit  18.3 3.7 100.0
 Proprietary 15.5 0.0 0.0
 Private 12.9 4.2 0.0
 Collapsed 35.1 92.0 0.0
Hospital Teaching Status    
  Teaching 18.2 100.0 100.0  
Case Mix Index 
 Mean (SD) 1.18 (0.001) 1.25 (0.001) 1.64 (0.18)
* Bed size and hospital control were categorized differently for each data source (see 
methods).  
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